

Vidofludimus

Catalog No: tcsc3221



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

717824-30-1

Formula:

$C_{20}H_{18}FNO_4$

Pathway:

Immunology/Inflammation

Target:

Interleukin Related

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 46 mg/mL (129.45 mM)

Alternative Names:

4sc-101;SC12267

Observed Molecular Weight:

355.36

Product Description


Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.

IC50 value:

Target: DHODH inhibitor

in vitro: 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes [2].

in vivo: In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells. In contrast, similarly reduced nuclear signal transducer and activator of transcription 3 (STAT3) binding and IL-17 levels were observed from animals treated with Vido alone and Vido + Uri. Vido improves TNBS-induced colonic inflammation by a unique dual mode of action [1]. Oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. In these colitis models the overall efficacy profile of 4SC-101 was similar to that of dexamethasone [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!